Berlin - Delayed Quote EUR

Ocean Biomedical Inc (8AW0.BE)

Compare
0.1810
-0.0550
(-23.31%)
As of January 30 at 9:40:08 PM GMT+1. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 8AW0.BE

Recent News: 8AW0.BE

View More
Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway

Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway
GlobeNewswire yesterday
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
GlobeNewswire 2 months ago
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter

Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
GlobeNewswire 3 months ago
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
GlobeNewswire 3 months ago
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms
GlobeNewswire 5 months ago
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024

Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
GlobeNewswire 7 months ago
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease
GlobeNewswire 8 months ago
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
GlobeNewswire 9 months ago
13 Hot Stocks to Invest in According to Wall Street Analysts

13 Hot Stocks to Invest in According to Wall Street Analysts
Insider Monkey 9 months ago
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL

Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
GlobeNewswire 9 months ago
Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting

Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting
GlobeNewswire 10 months ago
View More

Related Tickers

1VT.DU Viking Therapeutics Inc
32.15
-1.20%
 
2UV.F Applied Therapeutics, Inc.
0.5150
-2.00%
 
NV4.F Cellectar Biosciences, Inc.
0.2000
-9.91%
 
0M4.DU Mersana Therapeutics Inc
0.5906
+2.64%
 
NV4.MU Cellectar Biosciences Inc
0.2420
-3.20%
 
3G0.BE Altimmune Inc
6.71
-0.52%
 
M55.F MacroGenics, Inc.
2.8940
-5.67%
 
2UV.DU Applied Therapeutics Inc
0.5745
+2.96%
 
AT20.F Atara Biotherapeutics, Inc.
7.45
-5.70%
 
3G0.MU Altimmune Inc
6.63
0.00%